Cargando…

Plasma concentration guided dosing of drugs used for the treatment of childhood leukaemias: protocol for a systematic review

INTRODUCTION: Childhood leukaemia is the most common type of cancer in children and represents among 25% of the diagnoses in children <15 years old. Childhood survival rates have significantly improved within the last 40 years due to a rapid advancement in therapeutic interventions. However, in h...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dyk, Madelé, Boylan, Chelsea, Michelet, Robin, Mc Laughlin, Anna M, Kichenadasse, Ganessan, May, Nikki, Ziesenitz, Victoria, Van Den Anker, Johannes N, Groenland, Stefanie L, Huitema, Alwin D R, Steeghs, Neeltje, Mikus, Gerd, Kloft, Charlotte, Tapp, Heather
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724759/ https://www.ncbi.nlm.nih.gov/pubmed/34980620 http://dx.doi.org/10.1136/bmjopen-2021-053308

Ejemplares similares

Cost-effectiveness of oral anticancer drugs and associated individualised dosing approaches in patients with cancer: protocol for a systematic review
por: van Dyk, Madelé, et al.
Publicado: (2021)

Framework for Implementing Individualised Dosing of Anti-Cancer Drugs in Routine Care: Overcoming the Logistical Challenges
por: van Leuven, Jason, et al.
Publicado: (2023)

Therapeutic drug monitoring of oral targeted antineoplastic drugs
por: Mueller-Schoell, Anna, et al.
Publicado: (2020)

Harnessing soft tissue sarcoma with low-dose pazopanib – a matter of blood levels
por: Groenland, Stefanie L., et al.
Publicado: (2018)

Simulation-Based Assessment of the Impact of Non-Adherence on Endoxifen Target Attainment in Different Tamoxifen Dosing Strategies
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Computational Treatment Simulations to Assess the Need for Personalized Tamoxifen Dosing in Breast Cancer Patients of Different Biogeographical Groups
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years
por: Ziesenitz, Victoria C., et al.
Publicado: (2022)

Determination of the absolute bioavailability of oral imatinib using a stable isotopically labeled intravenous imatinib-d8 microdose
por: Roosendaal, Jeroen, et al.
Publicado: (2020)

Beta-adrenergic receptor blockade in angiosarcoma: Which beta-blocker to choose?
por: Embaby, Alaa, et al.
Publicado: (2022)

Ritonavir-Boosted Exposure of Kinase Inhibitors: an Open Label, Cross-over Pharmacokinetic Proof-of-Concept Trial with Erlotinib
por: Boosman, René J., et al.
Publicado: (2022)

Developing a Nationwide Infrastructure for Therapeutic Drug Monitoring of Targeted Oral Anticancer Drugs: The ON-TARGET Study Protocol
por: Mc Laughlin, Anna M., et al.
Publicado: (2021)

Microdialysis of Voriconazole and its N-Oxide Metabolite: Amalgamating Knowledge of Distribution and Metabolism Processes in Humans
por: Schulz, Josefine, et al.
Publicado: (2022)

Microdialysis of Drug and Drug Metabolite: a Comprehensive In Vitro Analysis for Voriconazole and Voriconazole N-oxide
por: Schulz, Josefine, et al.
Publicado: (2022)

Exposure–Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non‐Small Cell Lung Cancer Patients
por: Groenland, Stefanie L., et al.
Publicado: (2020)

CYP2D6 phenotype explains reported yohimbine concentrations in four severe acute intoxications
por: Mueller-Schoell, Anna, et al.
Publicado: (2021)

Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
por: Schulz, Josefine, et al.
Publicado: (2022)

Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data
por: Kluwe, Franziska, et al.
Publicado: (2023)

A Review of CYP3A Drug-Drug Interaction Studies: Practical Guidelines for Patients Using Targeted Oral Anticancer Drugs
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

The Use of Translational Modelling and Simulation to Develop Immunomodulatory Therapy as an Adjunct to Antibiotic Treatment in the Context of Pneumonia
por: Michelet, Robin, et al.
Publicado: (2021)

Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing
por: Verheijen, Remy B., et al.
Publicado: (2017)

PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma—a proof of principle study
por: Heinhuis, Kimberley M, et al.
Publicado: (2020)

Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: Verheijen, Remy B., et al.
Publicado: (2017)

Worse capecitabine treatment outcome in patients with a low skeletal muscle mass is not explained by altered pharmacokinetics
por: Molenaar‐Kuijsten, Laura, et al.
Publicado: (2021)

Pharmacokinetics of a microdosed cocktail of three direct oral anticoagulants in children with congenital heart defects: study protocol for a single-centre clinical trial (DOAC-Child)
por: Hermann, Simon A, et al.
Publicado: (2023)

Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial
por: Verheijen, Remy B., et al.
Publicado: (2017)

Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology
por: van der Kleij, Maud B. A., et al.
Publicado: (2023)

Radiation Induced Leiomyosarcoma Three Decades After Treatment for Wilms’ Tumor
por: Khattak, Muhammad A, et al.
Publicado: (2010)

Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report
por: Abbas, M. Nazim, et al.
Publicado: (2021)

Exposure–response analyses of cabozantinib in patients with metastatic renal cell cancer
por: Krens, Stefanie D., et al.
Publicado: (2022)

Minor contribution of cytochrome P450 3A activity on fentanyl exposure in palliative care cancer patients
por: Geist, Marcus J. P., et al.
Publicado: (2019)

Quantification of the Time Course of CYP3A Inhibition, Activation, and Induction Using a Population Pharmacokinetic Model of Microdosed Midazolam Continuous Infusion
por: Nassar, Yomna M., et al.
Publicado: (2022)

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
por: Janssen, Julie M., et al.
Publicado: (2022)

Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study
por: Mangoni, Arduino A., et al.
Publicado: (2018)

Artificial intelligence chatbots will revolutionize how cancer patients access information: ChatGPT represents a paradigm-shift
por: Hopkins, Ashley M, et al.
Publicado: (2023)

Early tumor shrinkage identifies long-term disease control and survival in patients with lung cancer treated with atezolizumab
por: Hopkins, Ashley M, et al.
Publicado: (2020)

Risk factors of proteinuria in renal cell carcinoma patients treated with VEGF inhibitors: a secondary analysis of pooled clinical trial data
por: Sorich, Michael J, et al.
Publicado: (2016)

Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials
por: Hopkins, Ashley M., et al.
Publicado: (2020)

Intra-Tumoral Pharmacokinetics of Pazopanib in Combination with Radiotherapy in Patients with Non-Metastatic Soft-Tissue Sarcoma
por: Molenaar-Kuijsten, Laura, et al.
Publicado: (2021)

Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients
por: Bins, Sander, et al.
Publicado: (2018)

ATX-101, a cell-penetrating protein targeting PCNA, can be safely administered as intravenous infusion in patients and shows clinical activity in a Phase 1 study
por: Lemech, Charlotte Rose, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hk48p0uah4m3rkgc4fd4md2blh